A Case Study Utilizing Exhaled Nitric Oxide-An Aid in Determining Asthma Treatment

2007 ◽  
Vol 119 (1) ◽  
pp. S174
Author(s):  
J. Bishop ◽  
B. Miller
Keyword(s):  
Nitric Oxide ◽  
Exhaled Nitric Oxide ◽  
Asthma Treatment

The Combined Impact of Exhaled Nitric Oxide and Sputum Eosinophils Monitoring in Asthma Treatment: A Prospective Cohort Study

2015 ◽  
Vol 21 (32) ◽  
pp. 4752-4762 ◽  
Author(s):  
Mario Malerba ◽  
Alessandro Radaeli ◽  
Alessia Olivini ◽  
Beatrice Ragnoli ◽  
Fabio Ricciardolo ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Cohort Study ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Exhaled Nitric Oxide ◽  
Asthma Treatment ◽  
Sputum Eosinophils ◽  
Combined Impact

scholarly journals Does treatment guided by exhaled nitric oxide fraction improve outcomes in subgroups of children with asthma?

2020 ◽  
Vol 55 (5) ◽  
pp. 1901879
Author(s):  
Shona S. Fielding ◽  
Marielle Pijnenburg ◽  
Johan de Jongste ◽  
Katherine Pike ◽  
Graham Roberts ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Standard Treatment ◽  
Exhaled Nitric Oxide ◽  
Loss Of Control ◽  
Asthma Treatment ◽  
Obese Children ◽  
Children With Asthma ◽  
Leukotriene Receptor ◽  
Asthma Outcomes ◽  
Using Data

IntroductionExhaled nitric oxide fraction (FENO), a biomarker of eosinophilic airway inflammation, may be useful to guide asthma treatment. FENO-guided treatment may be more effective in certain subgroups for improving asthma outcomes compared to standard treatment.MethodsAn individual patient data analysis was performed using data from seven randomised clinical trials (RCTs) which used FENO to guide asthma treatment. The incidence of an asthma exacerbation and loss of control, and the time to first exacerbation and loss of control were described between five subgroups of RCT participants.ResultsData were available in 1112 RCT participants. Among those not treated with leukotriene receptor antagonists (LTRA), but not among those who were treated with LTRA, FENO-guided treatment was associated with reduced exacerbation risk (OR 0.68, 95% CI 0.49–0.94), longer time to first exacerbation (hazard ratio (HR) 0.76, 95% CI 0.57–0.99) and borderline reduced risk for loss of control (OR 0.70, 95% CI 0.49–1.00). Nonobese children, compared to obese children, were less likely to lose asthma control when treatment was guided by FENO (OR 0.69, 95% CI 0.48–0.99) and time to loss of control was longer (HR 0.77, 95% CI 0.61–0.99).ConclusionsAsthma treatment guided by FENO may be more effective in achieving better asthma outcomes for patients who are not treated with LTRA and who are not obese, compared to standard practice.

Exhaled nitric oxide as a clinical biomarker for choosing biologics for severe asthma treatment

2020 ◽  
Vol 14 (7) ◽  
pp. 499-502
Author(s):  
Salvatore Fuschillo ◽  
Enrico Heffler ◽  
Mauro Maniscalco
Keyword(s):  
Nitric Oxide ◽  
Severe Asthma ◽  
Exhaled Nitric Oxide ◽  
Asthma Treatment ◽  
Clinical Biomarker

scholarly journals A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils)

Thorax ◽  
2010 ◽  
Vol 67 (3) ◽  
pp. 199-208 ◽  
Author(s):  
H L Petsky ◽  
C J Cates ◽  
T J Lasserson ◽  
A M Li ◽  
C Turner ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Systematic Review ◽  
Meta Analysis ◽  
Exhaled Nitric Oxide ◽  
Asthma Treatment ◽  
Sputum Eosinophils
Sign in / Sign up

Export Citation Format

Share Document